Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolaus Marx

Showing results (31-40 of 566) with videos related to

Pageof 57
Sort By:
Diabetologia|August 23, 2018
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseasesChristoph Wanner, Nikolaus Marx
The Review of Diabetic Studies : RDS|December 30, 2009
C-Peptide in the vessel wallDaniel Walcher, Nikolaus Marx
JACC. Basic to Translational Science|January 10, 2019
Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?Nikolaus Marx, Peter Libby
Experimental Diabetes Research|April 11, 2008
C-Peptide and atherogenesis: C-Peptide as a mediator of lesion development in patients with type 2 diabetes mellitus?Nikolaus Marx, Daniel Walcher
Progress in Lipid Research|July 20, 2007
Vascular effects of PPARgamma activators - from bench to bedsideNikolaus Marx, Daniel Walcher
The American Journal of Medicine|May 21, 2017
Diabetes Mellitus and Heart FailureMichael Lehrke, Nikolaus Marx
Diabetes & Vascular Disease Research|November 24, 2005
Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic actionDaniel Walcher, Nikolaus Marx
European Heart Journal|April 1, 2021
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trialNikolaus Marx, Jürgen Floege
Herz|June 10, 2021
Cardiovascular disease in patients with chronic kidney diseaseNikolaus Marx, Jürgen Floege
The Review of Diabetic Studies : RDS|January 21, 2012
Cardiovascular effects of incretin-based therapiesMichael Lehrke, Nikolaus Marx
Pageof 57

Showing results (31-40 of 566) with videos related to

Sort By:
Pageof 57
Diabetologia|August 23, 2018
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseasesChristoph Wanner, Nikolaus Marx
The Review of Diabetic Studies : RDS|December 30, 2009
C-Peptide in the vessel wallDaniel Walcher, Nikolaus Marx
JACC. Basic to Translational Science|January 10, 2019
Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?Nikolaus Marx, Peter Libby
Experimental Diabetes Research|April 11, 2008
C-Peptide and atherogenesis: C-Peptide as a mediator of lesion development in patients with type 2 diabetes mellitus?Nikolaus Marx, Daniel Walcher
Progress in Lipid Research|July 20, 2007
Vascular effects of PPARgamma activators - from bench to bedsideNikolaus Marx, Daniel Walcher
The American Journal of Medicine|May 21, 2017
Diabetes Mellitus and Heart FailureMichael Lehrke, Nikolaus Marx
Diabetes & Vascular Disease Research|November 24, 2005
Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic actionDaniel Walcher, Nikolaus Marx
European Heart Journal|April 1, 2021
Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trialNikolaus Marx, Jürgen Floege
Herz|June 10, 2021
Cardiovascular disease in patients with chronic kidney diseaseNikolaus Marx, Jürgen Floege
The Review of Diabetic Studies : RDS|January 21, 2012
Cardiovascular effects of incretin-based therapiesMichael Lehrke, Nikolaus Marx
Pageof 57